Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLIG3X)

Drug Name

3,5 DIBROMOTYROSINE Drug Info

Synonyms

3,5-DIBROMOTYROSINE; 2-amino-3-(3,5-dibromo-4-hydroxyphenyl)propanoic acid; 537-24-6; 3,5-Dibromo-tyrosine; NSC210786; 3,5-Dibromo-DL-tyrosine; Bromotiren; CHEMBL1253341; CHEBI:80912; L-Tyrosine,5-dibromo-; Tyrosine,5-dibromo-, L-; Dibromotirina; Biotiren; NSC-210786; EINECS 208-661-9; Tyrosine,5-dibromo-; .beta.-(3,5-Dibromo-4-hydroxyphenyl)alanine; ACMC-209hco; AC1L1W1Q; SCHEMBL145218; CTK7I4423; MolPort-002-887-590; NSC97935; ZX-AN012875; NSC39452; ALBB-014135; NSC-97935; NSC-39452; BDBM50326563; AKOS005109959; MS-3024

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 67532
ChEBI ID: CHEBI:28335
CAS Number: CAS 300-38-9
TTD Drug ID: DMLIG3X

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Erythropoietin Receptor (EPOR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Darbepoetin alfa	DMMJTYW	Anemia	3A00-3A9Z	Approved	[2]
Epoetin alfa	DMKWB73	Anemia	3A00-3A9Z	Approved	[3]
Methoxy polyethylene glycol-epoetin beta	DMK1LZD	Kidney transplant rejection	NE84	Approved	[4]
RHuEPO	DMALNG0	Solid tumour/cancer	2A00-2F9Z	Approved	[5]
ErepoXen	DM9YI2C	Anemia	3A00-3A9Z	Phase 3	[6]
Epoetin zeta	DM9QPOU	Anemia	3A00-3A9Z	Phase 3	[7]
Hematide	DMUE843	Anemia	3A00-3A9Z	Phase 3	[8]
Cibinetide	DMCFLRH	Depression	6A70-6A7Z	Phase 2	[9]
GlycoPEGylated erythropoietin	DM5JKCL	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[10]
Albupoietin	DMXK4CI	Anemia	3A00-3A9Z	Terminated	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Erythropoietin Receptor (EPOR)	TTAUX24	EPOR_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
2	A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation. Eur J Biochem. 1999 Jul;263(2):410-9.
3	2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. PediatrBlood Cancer. 2009 Jul;53(1):7-12.
4	2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718).
6	Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica. 2006 Aug;91(8):1076-83.
7	Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther. 2008 Nov;25(11):1215-28.
8	Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
9	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10	Design of Homogeneous, MonoPEGylated Erythropoietin Analogs With Preserved In Vitro Bioactivity. Exp Hematol. 2006 June; 34(6): 697-704.
11	Clinical pipeline report, company report or official report of cogenesys.